Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSPBI-4050 is an agonist of free fatty acid receptor 1 (FFAR1/GPR40) and an antagonist of G protein-coupled receptor 84 (GPR84).1 It induces β-arrestin-2 recruitment in a reporter assay using HEK293 cells expressing human FFAR1/GPR40 (EC50 = 275 µM). PBI-4050 inhibits activation of GPR84 induced by decanoic acid (Item No. 20838) or embelin (Item No. 11838) in reporter assays using HEK293 cells expressing the human receptor (IC50s = 398 and 209 µM, respectively). In vivo, PBI-4050 (200 mg/kg) decreases renal histological lesion scores in a mouse model of doxorubicin-induced nephrotoxicity. It also reduces tissue fibrosis in several additional in vivo rodent models, including carbon tetrachloride-induced hepatotoxicity and bleomycin-induced pulmonary fibrosis. PBI-4050 (100 mg/kg) decreases albuminuria, prevents decreases in the glomerular filtration rate (GFR) and podocyte numbers, and reduces blood glucose levels in a model of accelerated type 2 diabetes using eNos-/- db/db mice.2
WARNING This product is not for human or veterinary use.
1. A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84. Am. J. Pathol. 188(5), 1132-1148 (2018).
2. Fatty acid receptor modulator PBI-